KoBioLabs Inc

KoBioLabs Inc has a liquidity position that appears to be strong, with a current ratio of 3.22, indicating that the company holds more than three times as much in current assets as it does in current liabilities. However, the company's operating cash flow is negative at -4.2 billion KRW, and its free cash flow is also negative at -3.3 billion KRW, suggesting that the company is not generating sufficient cash from operations to fund its activities.

Profitability metrics for KoBioLabs Inc are negative, with a return on equity of -5.15% and a return on assets of -1.86%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's operating income is negative at -2.3 billion KRW, and its net income is also negative at -2.2 billion KRW, further highlighting the lack of profitability.

The company's capital structure is characterized by a debt-to-equity ratio of 0.59, which suggests that the company is financed more by equity than by debt. The total liabilities amount to 76.1 billion KRW, while the total equity is 43.0 billion KRW. The company's long-term debt is 25.5 billion KRW, and it has a significant amount of cash and equivalents at 29.2 billion KRW, which could be used to service its debt obligations.

KoBioLabs Inc's growth trajectory is not clearly defined, as the company has not provided specific revenue growth projections for the current or next fiscal year. The company's revenue for the latest period is 14.9 billion KRW, but the operating income and net income are both negative, indicating that the company is not growing profitably. The capital expenditure for the period is -1.5 billion KRW, which may suggest a reduction in investment in long-term assets.

The risk assessment for KoBioLabs Inc indicates a low level of liquidity risk, as the company has a strong current ratio and a significant amount of cash and equivalents. However, the company's profitability is a concern, and the negative operating and net income figures suggest that the company may face challenges in maintaining its operations. The dilution risk is also low, with no immediate filing-based liquidity or dilution flags detected.

There are no recent events or filings that have been disclosed for KoBioLabs Inc, which limits the ability to assess the company's recent performance or strategic direction. The company's financial performance and risk profile suggest that it may need to address its profitability and cash flow issues to sustain its operations.

Revenue grew at a 121.2% CAGR over four years, demonstrating strong historical top-line expansion capability.

Cash conversion ratio of 1.9 exceeds the Food Processing cohort median of 0.98, indicating superior cash generation efficiency.

Debt-to-equity ratio of 0.59 is below the cohort median of 0.32, suggesting a manageable leverage position relative to peers.

Long-term debt decreased to 9.2 billion KRW in FY-4, showing a historical trend of debt reduction during earlier periods.

Gross profit reached 51.1 billion KRW in FY0, maintaining a substantial buffer before operating expenses impact net income.

The company carries a high credit risk flag, suggesting significant concerns regarding its ability to meet financial obligations.

Return on equity of -5.15% ranks in the bottom quartile of the cohort, reflecting poor capital efficiency for shareholders.